CCCC - C4 Therapeutics  - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

CCCC is currently covered by 8 analysts with an average price target of $15.51. This is a potential upside of $12.75 (461.96%) from yesterday's end of day stock price of $2.76.

C4 Therapeutics 's activity chart (see below) currently has 41 price targets and 44 ratings on display. The stock rating distribution of CCCC is 38.46% HOLD and 61.54% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 34.09% with an average time for these price targets to be met of 42.73 days.

Highest price target for CCCC is $12, Lowest price target is $12, average price target is $11.57.

Most recent stock forecast was given by DEREK ARCHILA from WELLS FARGO on 19-Dec-2024. First documented stock forecast 27-Oct-2020.

Currently out of the existing stock ratings of CCCC, 5 are a HOLD (38.46%), 8 are a BUY (61.54%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$12

$9.54 (387.80%)

$8

8 months ago
(19-Dec-2024)

4/6 (66.67%)

$8.15 (211.69%)

147

Buy

$20

$17.54 (713.01%)

1 years 13 days ago
(06-Aug-2024)

0/2 (0%)

$14 (233.33%)

Buy

$14

$11.54 (469.11%)

$13

1 years 3 months 10 days ago
(09-May-2024)

4/8 (50%)

$7.2 (105.88%)

102

Buy

$14

$11.54 (469.11%)

$15

1 years 5 months 15 days ago
(04-Mar-2024)

1/3 (33.33%)

$3.32 (31.09%)

29

$8

$5.54 (225.20%)

$3

1 years 5 months 24 days ago
(26-Feb-2024)

4/4 (100%)

$-1.51 (-15.88%)

39

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is CCCC (C4 Therapeutics ) average time for price targets to be met?

On average it took 42.73 days on average for the stock forecasts to be realized with a an average price target met ratio 34.09

Which analyst has the current highest performing score on CCCC (C4 Therapeutics ) with a proven track record?

DEREK ARCHILA

Which analyst has the most public recommendations on CCCC (C4 Therapeutics )?

Derek Archila works at WELLS FARGO and has 8 price targets and 5 ratings on CCCC

Which analyst is the currently most bullish on CCCC (C4 Therapeutics )?

Matthew Luchini with highest potential upside - $112.14

Which analyst is the currently most reserved on CCCC (C4 Therapeutics )?

Colin Bristow with lowest potential downside - -$0

C4 Therapeutics  in the News

C4 Therapeutics GAAP EPS of -$0.37

* C4 Therapeutics press release [https://seekingalpha.com/pr/20192750-c4-therapeutics-reports-second-quarter-2025-financial-results-and-recent-business-highlights] (NASDAQ:CCCC [https://seekingalpha.com/symbol/CCCC]): Q2 GAAP EPS of -$0.37. * Cash, cash equivalents and marketable securities as of June 30, 2025 were $223.0 million, compared to $234.7 million as of March 31, 2025 and $267.3 million as of December 31, 2024. *   MORE ON C4 THERAPEUTICS * C4 Therapeutics: An...

C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

C4 Therapeutics, Inc. Cemsidomide Phase 1 Data in Multiple Myeloma Accepted as an Oral Presentation at the International Myeloma Society (IMS) Annual Meeting; As of the July 23, 2025, Data Cutoff, Phase 1 ORR Remains at 40% at the 75 µg Dose Level and at 50% at the 100 µg Dose Level Productive Type C...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?